{"id":56133,"date":"2026-02-03T16:14:20","date_gmt":"2026-02-03T08:14:20","guid":{"rendered":"https:\/\/flcube.com\/?p=56133"},"modified":"2026-02-03T16:14:20","modified_gmt":"2026-02-03T08:14:20","slug":"novartis-cosentyx-wins-nmpa-approval-for-non-radiographic-axial-spondyloarthritis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56133","title":{"rendered":"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis"},"content":{"rendered":"\n<p><strong>Novartis<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE:\u202fNVS<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>Cosentyx (secukinumab)<\/strong> for adult patients with <strong>active, non-radiographic axial spondyloarthritis (nr-axSpA)<\/strong> who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and exhibit objective signs such as elevated C-reactive protein (CRP) and\/or MRI evidence.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Novartis (NYSE:\u202fNVS)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Cosentyx (secukinumab)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Interleukin-17A (IL-17A) inhibitor<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Active nr-axSpA in adults<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>NMPA marketing authorization<\/td><\/tr><tr><td><strong>Previous Approvals<\/strong><\/td><td>Plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa<\/td><\/tr><tr><td><strong>Clinical Basis<\/strong><\/td><td>Global Phase III PREVENT study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-prevent-study-key-efficacy-data\">PREVENT Study Key Efficacy Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Comparison<\/th><\/tr><\/thead><tbody><tr><td><strong>ASAS40 Response at Week 16<\/strong><\/td><td>40.0%<\/td><td>vs. 28.0% placebo (P &lt; 0.05)<\/td><\/tr><tr><td><strong>Sustained Improvement<\/strong><\/td><td>Through Week 52<\/td><td>Maintained efficacy<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Significant improvements<\/td><td>Pain, physical mobility, health-related quality of life<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Favorable<\/td><td>Consistent with known safety profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China nr-axSpA Market:<\/strong> Estimated <strong>\u00a53\u20135\u202fbillion<\/strong> : (~US$420\u2013700\u202fmillion) by 2028, driven by improved diagnosis and biologic adoption<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>TNF inhibitors<\/strong> and <strong>IL-17 inhibitors<\/strong>; Cosentyx&#8217;s established safety profile offers advantage<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Expands Cosentyx&#8217;s immunology franchise in China; positions Novartis as leader in axial spondyloarthritis management<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a51.5\u20132.0\u202fbillion<\/strong> (US$210\u2013280\u202fmillion) peak annual sales for nr-axSpA indication by 2030<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Estimated <strong>300,000\u2013500,000<\/strong> nr-axSpA patients in China with inadequate NSAID response<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Commercial launch expected <strong>Q2\u202f2026<\/strong>; physician education programs targeting rheumatologists to commence immediately<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market penetration, and revenue projections for Cosentyx in China. Actual results may differ due to competitive dynamics, market adoption rates, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis (NYSE:\u202fNVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56134,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,140,865,15],"class_list":["post-56133","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-novartis","tag-nyse-nvs","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis (NYSE:\u202fNVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for adult patients with active, non-radiographic axial spondyloarthritis (nr-axSpA) who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and exhibit objective signs such as elevated C-reactive protein (CRP) and\/or MRI evidence.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56133\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis\" \/>\n<meta property=\"og:description\" content=\"Novartis (NYSE:\u202fNVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for adult patients with active, non-radiographic axial spondyloarthritis (nr-axSpA) who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and exhibit objective signs such as elevated C-reactive protein (CRP) and\/or MRI evidence.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56133\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T08:14:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis\",\"datePublished\":\"2026-02-03T08:14:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0301.webp\",\"keywords\":[\"Auto-immune\",\"Novartis\",\"NYSE: NVS\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56133#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56133\",\"name\":\"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0301.webp\",\"datePublished\":\"2026-02-03T08:14:20+00:00\",\"description\":\"Novartis (NYSE:\u202fNVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for adult patients with active, non-radiographic axial spondyloarthritis (nr-axSpA) who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and exhibit objective signs such as elevated C-reactive protein (CRP) and\\\/or MRI evidence.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56133\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0301.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56133#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis (NYSE:\u202fNVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for adult patients with active, non-radiographic axial spondyloarthritis (nr-axSpA) who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and exhibit objective signs such as elevated C-reactive protein (CRP) and\/or MRI evidence.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56133","og_locale":"en_US","og_type":"article","og_title":"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis","og_description":"Novartis (NYSE:\u202fNVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for adult patients with active, non-radiographic axial spondyloarthritis (nr-axSpA) who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and exhibit objective signs such as elevated C-reactive protein (CRP) and\/or MRI evidence.","og_url":"https:\/\/flcube.com\/?p=56133","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-03T08:14:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56133#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56133"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis","datePublished":"2026-02-03T08:14:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56133"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56133#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0301.webp","keywords":["Auto-immune","Novartis","NYSE: NVS","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56133#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56133","url":"https:\/\/flcube.com\/?p=56133","name":"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56133#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56133#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0301.webp","datePublished":"2026-02-03T08:14:20+00:00","description":"Novartis (NYSE:\u202fNVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for adult patients with active, non-radiographic axial spondyloarthritis (nr-axSpA) who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) and exhibit objective signs such as elevated C-reactive protein (CRP) and\/or MRI evidence.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56133#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56133"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56133#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0301.webp","width":1080,"height":608,"caption":"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56133#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56133"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56133\/revisions"}],"predecessor-version":[{"id":56135,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56133\/revisions\/56135"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56134"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}